Vertex Pharmaceuticals' products are constantly in high demand. The company's portfolio should help drive revenue growth for a while. It also has an exciting pipeline that will help it diversify ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%. Is there a buying ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...

Vertex Pharmaceuticals (Nasdaq ... Casgevy’s build-out and further launches of new products in 2025 and 2026, Vertex now seems set for steady profitable growth. There is no dividend.

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical ...